In its quarterly qualitative update, Lonza reported a softer Q1, with performance across H1 expected to align with the full-year 2024 trajectory. Lonza confirms its 2024 outlook, projecting flat sales…
The Bayer Group’s performance in the first quarter of the year met expectations, according to CEO Bill Anderson. “First-quarter sales declined slightly versus the prior year. The Pharmaceuticals Division saw…
Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, global option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including…
Sanofi, the largest private contributor to France’s health ecosystem security and independence, announced a €1 billion investment to expand bioproduction at its sites in Vitry-sur-Seine, Le Trait, and Lyon Gerland.…
AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals have announced a collaboration and option-to-license agreement aimed at developing next-generation therapies for psychiatric disorders. This partnership combines AbbVie’s psychiatric expertise with Gilgamesh’s innovative…
Novo Nordisk announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a study involving 254 participants over 26 weeks. This open-label, randomized, controlled, multi-arm trial assessed the…
The anticipated growth of the global PEGylated proteins market is significant, with projections indicating a rise from $10.2 billion in 2023 to $15.9 billion by 2028, reflecting a robust compound…
Be Biopharma, Inc. (“Be Bio”), a trailblazing company in the development of Engineered B Cell Medicines (BCMs), unveiled new preclinical findings today, showcasing the production of active ALP by a…
A clinical-stage biopharmaceutical company, specializing in the advancement and market introduction of seralutinib for the management of pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD),…
Revelation Biosciences, Inc. (NASDAQ: REVB), a clinical-stage life sciences firm dedicated to leveraging trained immunity for disease prevention and treatment, released its financial results for the three months ending March…
A leading performance beauty enterprise, specializing in curating an aesthetic range of consumer brands, has announced the allocation of non-qualified stock options for the acquisition of a combined total of…
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) disclosed today that its Compensation Committee, a part of Mirum’s Board of Directors, has authorized the allocation of inducement awards to 11 new recruits under…